Abstract
The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.
| Original language | English |
|---|---|
| Pages (from-to) | 2756-2770 |
| Number of pages | 15 |
| Journal | Frontiers in Bioscience |
| Volume | 16 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jun 1 2011 |
Fingerprint
Keywords
- Advanced Glycation End-products
- Alternative splicing
- mRNA
- Receptors
- Review
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Immunology and Microbiology(all)
- Medicine(all)
Cite this
Alternative splicing of RAGE : Roles in biology and disease. / Kalea, Anastasia Z.; Schmidt, Ann Marie; Hudson, Barry.
In: Frontiers in Bioscience, Vol. 16, No. 7, 01.06.2011, p. 2756-2770.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Alternative splicing of RAGE
T2 - Roles in biology and disease
AU - Kalea, Anastasia Z.
AU - Schmidt, Ann Marie
AU - Hudson, Barry
PY - 2011/6/1
Y1 - 2011/6/1
N2 - The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.
AB - The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.
KW - Advanced Glycation End-products
KW - Alternative splicing
KW - mRNA
KW - Receptors
KW - Review
UR - http://www.scopus.com/inward/record.url?scp=79959567198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959567198&partnerID=8YFLogxK
U2 - 10.2741/3884
DO - 10.2741/3884
M3 - Article
VL - 16
SP - 2756
EP - 2770
JO - Frontiers in Bioscience - Landmark
JF - Frontiers in Bioscience - Landmark
SN - 1093-9946
IS - 7
ER -